Ocular Therapeutix (OCUL) Enterprise Value (2013 - 2026)
Ocular Therapeutix's quarterly Enterprise Value came in at -$666.7 million in Q1 2026, down 90.66% year-on-year from -$7.1 billion in Q1 2025, and up 9.55% quarter-over-quarter from -$737.1 million in Q4 2025.
Ocular Therapeutix has reported Enterprise Value for 14 years, with the latest figure at -$666.7 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value fell 90.66% year-over-year to -$666.7 million; the trailing twelve-month figure through Mar 2026 stood at -$666.7 million (down 90.66% YoY), and the FY2025 full-year result was -$737.1 million, down 87.98% from the prior year.
- Enterprise Value for Q1 2026 stood at -$666.7 million, up from -$737.1 million in the prior quarter.
- The five-year high for Enterprise Value was -$66.6 million in Q2 2023, with the low at -$737.1 million in Q4 2025.
- Average Enterprise Value over 5 years is -$306.3 million, with a median of -$344.8 million recorded in 2025.
- Year-over-year, Enterprise Value soared 50.49% in 2023 and slumped 590.16% in 2024.
- Tracing OCUL's Enterprise Value over 5 years: stood at -$102.3 million in 2022, then tumbled by 91.55% to -$196.0 million in 2023, then slumped by 100.1% to -$392.1 million in 2024, then plunged by 87.98% to -$737.1 million in 2025, then rose by 9.55% to -$666.7 million in 2026.
- The last three Enterprise Value figures came in at -$666.7 million (Q1 2026), -$737.1 million (Q4 2025), and -$344.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | -666.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -666.70 Mn |
| Dec 31, 2025 | -737.06 Mn |
| Sep 30, 2025 | -344.77 Mn |
| Jun 30, 2025 | -391.13 Mn |
| Mar 31, 2025 | -349.68 Mn |
| Dec 31, 2024 | -392.10 Mn |
| Sep 30, 2024 | -427.22 Mn |
| Jun 30, 2024 | -459.69 Mn |
| Mar 31, 2024 | -483.04 Mn |
| Dec 31, 2023 | -195.96 Mn |
| Sep 30, 2023 | -110.55 Mn |
| Jun 30, 2023 | -66.61 Mn |
| Mar 31, 2023 | -79.03 Mn |
| Dec 31, 2022 | -102.30 Mn |
| Sep 30, 2022 | -120.95 Mn |
| Jun 30, 2022 | -134.54 Mn |
| Mar 31, 2022 | -145.42 Mn |
| Dec 31, 2021 | -164.16 Mn |
| Sep 30, 2021 | -179.28 Mn |
| Jun 30, 2021 | -191.86 Mn |
| Mar 31, 2021 | -209.38 Mn |
| Dec 31, 2020 | -228.06 Mn |
| Sep 30, 2020 | -70.64 Mn |
| Jun 30, 2020 | -84.29 Mn |
| Mar 31, 2020 | -48.15 Mn |
| Dec 31, 2019 | -54.44 Mn |
| Sep 30, 2019 | -65.41 Mn |
| Jun 30, 2019 | -61.77 Mn |
| Mar 31, 2019 | -76.25 Mn |
| Dec 31, 2018 | -54.06 Mn |
| Sep 30, 2018 | -56.86 Mn |
| Jun 30, 2018 | -56.83 Mn |
| Mar 31, 2018 | -62.91 Mn |
| Dec 31, 2017 | -41.54 Mn |
| Sep 30, 2017 | -51.17 Mn |
| Jun 30, 2017 | -66.05 Mn |
| Mar 31, 2017 | -80.38 Mn |
| Dec 31, 2016 | -68.15 Mn |
| Sep 30, 2016 | -75.75 Mn |
| Jun 30, 2016 | -83.89 Mn |
| Mar 31, 2016 | -95.46 Mn |
| Dec 31, 2015 | -105.06 Mn |
| Sep 30, 2015 | -113.64 Mn |
| Jun 30, 2015 | -123.72 Mn |
| Mar 31, 2015 | -67.42 Mn |
| Dec 31, 2014 | -74.83 Mn |
| Sep 30, 2014 | -80.89 Mn |
| Jun 30, 2014 | -19.94 Mn |
| Mar 31, 2014 | -12.75 Mn |
| Dec 31, 2013 | -17.51 Mn |
| Sep 30, 2013 | -21.62 Mn |
| Jun 30, 2013 | -25.03 Mn |